Recent News

• 09.10.2025 - Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
• 09.05.2025 - Artelo Biosciences Announces Closing of $3.0 Million Public Offering
• 09.04.2025 - Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
• 09.03.2025 - Artelo Biosciences Announces Proposed Underwritten Public Offering
• 09.03.2025 - Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
• 09.03.2025 - Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
• 08.25.2025 - Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
• 08.13.2025 - Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
• 08.11.2025 - Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Recent Filings

• 09.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.05.2025 - 8-K Current report
• 09.05.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.03.2025 - 8-K Current report
• 08.29.2025 - 8-K Current report
• 08.20.2025 - 8-K Current report
• 08.13.2025 - D Notice of Exempt Offering of Securities
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]